HippoFi Welcomes Scott Bauccio As New Head of Sales for PUR Biologics

Jan 23, 2024

Full Story HERE…

HippoFi Ships International Orders and Expects Sales to Exceed $20 Million In the New Year

Biotechnology business PUR Biologics, began selling and shipping products for international use, closing out a phenomenal year of accomplishments.

Dec 11, 2023

Full Story HERE…

HippoFi Continues to Deliver Sales Growth Adding 14 Major Healthcare Facilities

Expanding our reach in 2024, HippoFi and PUR Biologics are setting new standards in innovative spine care solutions.

Dec 5, 2023

Full Story HERE…

Dr. Gail Naughton, world-renowned authority in the multibillion-dollar regenerative medicine market, joins HippoFi

Nov 7, 2023

Full Story HERE…

International Sales Win for PUR Biologics

Oct 24, 2023

Following a successful engagement at the North American Spine Society (NASS) conference, healthcare technology company, HippoFi, Inc., announces it has expanded its sales to include several notable international…

Full Story HERE…

PUR Biologics Secures Innovative Medical Patent with Strong Financial Upside

Sept 12, 2023

Solidifying its role as a leader in medical advancements, PUR Biologics, a wholly-owned subsidiary of HippoFi, proudly announces its latest patent acquisition, further strengthening its reputation in the biotech sector… 

…

HippoFi Announces Strategic Alliance to Lead Spinal Biologics Innovation

Sept 6, 2023

HippoFi, Inc. proudly announces a partnership with global medical technology leader ZIMMER BIOMET… 

…

HippoFi to Announce Strategic Alliance with Orthopedic Leader

Sept 1, 2023

HippoFi, in association with its wholly owned subsidiary PUR Biologics, is preparing to unveil the details of the closing of its strategic partnership and asset acquisition with a top 5 global leader… 

…

US Patent Office Issues New Patent to PUR Biologics for Advanced Cartilage Regeneration and Arthritis Solutions

Aug 14, 2023

…Newly granted patent, marking a significant advancement in addressing the debilitating effects of osteoarthritis and cartilage degeneration…

…

HippoFi Finalizes an Exclusive Strategic Partnership with International Biomedical Manufacturing Company, BPB Medica

Aug 9, 2023

…

HippoFi is Finalizing Definitive Agreements to Join Forces with Industry Giant to Revolutionize the Spinal Biologic Market

July 25, 2023

HippoFi, a healthcare technology and innovation firm focused on the sale of biologic products used for Spine surgery, entered the final phase of negotiations for definitive agreements …

HippoFi anticipates a New Strategic Partnership as the Company Prepares to Launch PURmarrow360, a Patented Stem Cell Harvesting Device

July 25, 2023

…this product is a natural extension to our robust product line, allowing surgeons to safely and selectively capture the highly desired cells from a patient’s own BMA during surgery…

HippoFi’s PUR Biologics Granted National Approval at the Veterans Health Administration (VHA), the Largest Integrated Healthcare System in the United States

June 27, 2023

PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough ™

May 9, 2023

PUR Biologics, an innovative biotech company, and wholly-owned subsidiary of HippoFi, Inc. (OTC PINK: ORHB), today has unveiled its latest product, PURbonedough™, to further expand its leadership into the burgeoning spine biologics market… 

…

PUR Biologics Expands Sales Network by 15% Adding 32 New Distributors

April 27, 2023

The addition of 32 new distributors to PUR Biologics’ distribution network is a testament to the growing demand for its high-quality products and expertise in ortho-spine biologics. With these new distributors, PUR Biologics has significantly increased its reach and access to new customers…

US Patent Office Grants PUR Biologics’ Breakthrough Patent for Activating Immune Cells 

April 19, 2023

This issued patent launches PUR Biologics into the field of cell and immune therapies, ushering in a new era of medical treatments for patients with immune compromised and chronic pain conditions.

PUR Biologics Launches PURfiberXP ^TM, A Best-in-Class Cortical Fiber Matrix for Bone Regeneration

April 13, 2023

“PURfiberXP ^TM is a highly specialized biologic derived from cortical bone fibers using a proprietary process,” shared Ryan Fernan, Head of PUR Biologics.

HippoFi Announces Its Return to Pink Current Information Tier on the OTC Market

April 11, 2023

Achieving this status is a testament to HippoFi’s commitment to excellence and transparency. “We are incredibly proud to have achieved Pink Current status with OTCMarkets, which is a significant milestone in our journey to create long-term value for our shareholders,” said CJ Wiggins, Executive Chairman & CEO of HippoFi.

PUR Biologics Announces Launch of PURcore ^TM, a bioActive Moldable Synthetic for Spine Surgery

April 6, 2023

PURcoreTM allows for the rapid colonization of the patient’s own cells and growth factors which promotes bone regeneration and healing.

ORHUB’S RYAN FERNAN BECOMES HEAD OF PUR BIOLOGICS, LEADING REGENERATIVE THERAPEUTIC EFFORTS

A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.

HIPPOFI BEGINS 2023 WITH STRONG SALES OF ADVANCED BIOMATERIALS

January 12, 2023

“Expanded Salesforce Fuels Market Growth”